Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Hugo Hool"'
Autor:
Zishuo Ian Hu, Johanna C. Bendell, Andrea Bullock, Noelle K. LoConte, Hassan Hatoum, Paul Ritch, Hugo Hool, Joseph W. Leach, James Sanchez, Davendra P. S. Sohal, John Strickler, Ravindranath Patel, Andrea Wang‐Gillam, Irfan Firdaus, Kenneth H. Yu, Ann M. Kapoun, Eric Holmgren, Lei Zhou, Jakob Dupont, Vincent Picozzi, Vaibhav Sahai, Eileen M. O'Reilly
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Abstract Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and Methods Aphase 2, randomized, placebo‐cont
Externí odkaz:
https://doaj.org/article/65d331d0de7c4b2799fe21f23c85e265
Autor:
Heather McArthur, Jorge Henrique Santos Leal, Christina DiLauro Abaya, Sangeetha Reddy, Meredith Carter, Reva Basho, Michelle Phillips, David Chan, Hugo Hool, Dorothy Park, Mary El-Masry, Philomena McAndrew, Swati Sikaria, Laura M. Spring, Aditya Bardia, Mourad Tighiouart, Farnaz Dadmanesh, Armando Giuliano, Stephen Shiao, David B. Page
Publikováno v:
Cancer Research. 83:OT3-25
Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) was safe and demonstrated modest activity in H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec0eafc437342ed32a50859c7ae9b8a1
https://doi.org/10.1158/1538-7445.sabcs22-ot3-25-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-25-01
Autor:
Kenneth H. Yu, James Sanchez, Jakob Dupont, Hassan Hatoum, Noelle K. LoConte, Eric Holmgren, Zishuo Ian Hu, Davendra Sohal, Paul S. Ritch, Andrea Wang-Gillam, John H. Strickler, Ravindranath Patel, Irfan Firdaus, Hugo Hool, Lei Zhou, Ann M. Kapoun, Andrea J. Bullock, Johanna C. Bendell, Eileen M. O'Reilly, Vaibhav Sahai, Joseph W. Leach, Vincent J. Picozzi
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5148-5157 (2019)
Purpose Notch signaling dysregulation is implicated in the development of pancreatic adenocarcinoma (PDAC). Tarextumab is a fully human IgG2 antibody that inhibits Notch2/3 receptors. Patients and methods Aphase 2, randomized, placebo-controlled, mul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb7748aa0df0a22e8c7055c2c6417ecb
http://europepmc.org/articles/PMC6718621
http://europepmc.org/articles/PMC6718621
Autor:
Zev A. Wainberg, David Ferry, Ravindranath Patel, Denis Pezet, Elzbieta Wojcik, Kazumasa Fujitani, Vera Gorbounova, Fernando Cabanillas, Bela Piko, Fidel David Huitzil Melendez, Agnes Ruzsa, Jean-Marc Phelip, Madhuri Bajaj, J.T. Beck, Elizabeth Won, Alexander Luft, Sara Lonardi, Peter C. Enzinger, Maen A. Hussein, Bohuslav Melichar, Daisuke Sakai, Angel Gomez Villanueva, A Madi, Georgina Garnica Jaliffe, Carlo Barone, Guillermo Mendez, Marina N. Nechaeva, György Bodoky, Hubert Ayala, Francesco Di Costanzo, Julien Taieb, David H. Ilson, Leslie Samuel, Ronald L. Burkes, Mayukh Das, Marc Van den Eynde, Charles S. Fuchs, Scott M. Berry, Ji Lin, Shuichi Hironaka, Christina Maria Gomez, Thierry Alcindor, Eric Van Cutsem, James A. Jr Reeves, Katriina Peltola, Timothy R. Asmis, Christine Brezden-Masley, Udit Verma, Javier Gallego Plazas, Isabelle Sinapi, Peter Bono, Nozomu Machida, Cynthia Coo Chua, Francisco Javier Ramirez Godinez, Annemieke Cats, Raija Kallio, Alex Beny, Hiroki Hara, Cardellino Giovanni Gerardo, Diego Lucas Kaen, Wasat Mansoor, Miguel Angel Escudero, Andràs Csilla, Akihito Tsuji, Ralf-Dieter Hofheinz, Jana Pribylova, Marianne Nordsmark, Daniel Dammrich, Maria Alejandra Bartoli, Joanna Pikiel, Robert Andrew Dichmann, Maria Di Bartolomeo, Ricardo Villalobos Valencia, Jill Lacy, Raymond Jang, Carlos Alberto Hernandez, Giuseppe Aprile, Nina A. Karaseva, Jonathan Wadsley, Ian Chau, Svetlana Protsenko, Jana Prausová, Maria Błasińska-Morawiec, Salah-Eddin Al-Batran, Hélène Senellart, Stephen Leong, Francisco Gutiérrez Delgado, Johanna C. Bendell, Laurent Mineur, M.I. Grootscholten, Hugo Ford, Russell D. Petty, Laura Visa Turmo, Roberto Carlesi, Hector Velez-Cortez, Maria Alsina, Jiri Petera, Seigo Yukisawa, Federico Longo Munoz, Mette Karen Yilmaz, Pilar Garcia Alfonso, Baruch Brenner, Irfan Firdaus, William E. Lawler, Sylvie Lorenzen, Moustapha Tehfe, Kohei Shitara, Naotoshi Sugimoto, Karen Geboes, A.J. Ten Tije, Walid Shaib, Shigenori Kadowaki, Nicolas Robert Maisey, H.M.W. Van Laarhoven, Radka Obermannova, F.L.G. Erdkamp, Rubén Dario Kowalyszyn, Joanna Wojcik-Tomaszewska, Peter Istvan Acs, Crystal S. Denlinger, Ravit Geva, Srinivasan Madhusudan, Brian Anthony DiCarlo, Ferdinando De Vita, Alejandro Molina Alavez, Gunnar Folprecht, Kensei Yamaguchi, Moses Sundar Raj, Judit Kocsis, Susanna Hegewisch-Becker, Joana Vidal Barrull, Daisuke Takahari, Tomasz Sarosiek, Luis Fein, Mohamed Hebbar, Tibor Csoszi, Manish A. Shah, Alfredo Falcone, Hugo Hool, Michel Ducreux, Per Pfeiffer, Einat Shacham-Shmueli, Howard J. Lim, Taito Esaki
Publikováno v:
The Lancet Oncology, 20(3), 420-435. Lancet Publishing Group
Summary Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32e40b7f9384317e149edcc0dc8725d0
https://doi.org/10.1016/s1470-2045(18)30791-5
https://doi.org/10.1016/s1470-2045(18)30791-5
Autor:
Heather L. McArthur, Jorge Henrique S. Leal, David B. Page, Christina DiLauro Abaya, Reva K Basho, Michelle Phillips, David Chan, Hugo Hool, Dorothy J. Park, Mary El-Masry, Philomena McAndrew, Swati Sikaria, Laura Spring, Aditya Bardia, Mourad Tighiouart, Farnaz Dadmanesh, Armando E. Giuliano, Stephen Lawrence Shiao
Publikováno v:
Journal of Clinical Oncology. 40:TPS624-TPS624
TPS624 Background: Immune checkpoint inhibition (ICI) is synergistic with HER2-directed therapy in pre-clinical models. Clinically, pembrolizumab (K)-mediated ICI plus HER2-directed therapy with trastuzumab (H) was safe and demonstrated modest activi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58d65823e10128665812ca7659f8cfe7
https://doi.org/10.1200/jco.2022.40.16_suppl.tps624
https://doi.org/10.1200/jco.2022.40.16_suppl.tps624
Autor:
Nicholas J. Vogelzang, Mark R. Olsen, Joshua J. McFarlane, Edward Arrowsmith, Todd M. Bauer, Rohit K. Jain, Bradley Somer, Elaine T. Lam, Mark D. Kochenderfer, Ana Molina, Gurjyot Doshi, Brian Lingerfelt, Ralph J. Hauke, Vijay Gunuganti, Ian Schnadig, Peter Van Veldhuizen, Mark Fleming, Robert Galamaga, Mukul Gupta, Hugo Hool, Thomas Hutson, Joshua Zhang, M. Brent McHenry, Jennifer L. Johansen, Scott S. Tykodi
Publikováno v:
Clinical genitourinary cancer. 18(6)
Background The open-label, phase IIIb/IV CheckMate 374 study (NCT02596035) was conducted to validate the safety and efficacy of flat-dose nivolumab monotherapy 240 mg every 2 weeks (Q2W) in previously treated advanced/metastatic renal cell carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e2375c7bc5ed92e4e42d211e83e78de
https://pubmed.ncbi.nlm.nih.gov/32718906
https://pubmed.ncbi.nlm.nih.gov/32718906
Autor:
Vaibhav Sahai, Noelle K. LoConte, Vincent J. Picozzi, Eric Holmgren, Paul S. Ritch, Ann M. Kapoun, John H. Strickler, James Sanchez, Jakob Dupont, Joseph W. Leach, Ravindranath Patel, Davendra Sohal, Johanna C. Bendell, Hassan Hatoum, Irfan Firdaus, Hugo Hool, Lei Zhou, Andrea Wang-Gillam, Andrea J. Bullock, Eileen M. O'Reilly
Publikováno v:
Journal of Clinical Oncology. 35:279-279
279 Background: Tarextumab (TRXT), fully human IgG2 antibody inhibits signaling of Notch2/ 3 receptors. Tumor regression seen in Notch3 (N3) expressing pt-derived pancreatic cancer xenografts when TRXT combined with Nab-P+Gem. Phase 2, randomized, pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94f5749f084d26e520a6c60b26857ae5
https://doi.org/10.1200/jco.2017.35.4_suppl.279
https://doi.org/10.1200/jco.2017.35.4_suppl.279